

Metabolite T₂ relaxation times decrease across the adult lifespan in a large multi-site cohort

Kathleen E. Hupfeld^{a,b†}, Saipavitra Murali-Manohar^{a,b†}, Helge J. Zöllner^{a,b}, Yulu Song^{a,b},
Christopher W. Davies-Jenkins^{a,b}, Aaron T. Gudmundson^{a,b,c}, Dunja Simičić^{a,b}, Gizeaddis
Simegn^{a,b}, Emily E. Carter^d, Steve C. N. Hui^{e,f,g}, Vivek Yedavalli^a, Georg Oeltzschner^{a,b},
Eric C. Porges^{d,h}, and Richard A. E. Edden^{a,b}

^a Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA

^b F. M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, MD, USA

^c The Malone Center for Engineering in Healthcare, Johns Hopkins University, Baltimore, MD, USA

^d Department of Clinical and Health Psychology, College of Public Health and Health Professions, University of Florida, Gainesville, Florida, USA

^e Developing Brain Institute, Children's National Hospital, Washington, D.C. USA

^f Department of Radiology, The George Washington University School of Medicine and Health Sciences, Washington, D.C. USA

^g Department of Pediatrics, The George Washington University School of Medicine and Health Sciences, Washington, D.C. USA

^h Center for Cognitive Aging and Memory, College of Medicine, University of Florida, Gainesville, Florida, USA

[†] Kathleen E. Hupfeld and Saipavitra Murali-Manohar contributed equally to this work.

Corresponding Author: Richard A. E. Edden, PhD
Russell H. Morgan Department of Radiology and Radiological Science
Johns Hopkins University School of Medicine, Baltimore, MD, USA 21287-0005
Email: raee2@jhu.edu

Running Title: T₂ CHANGES WITH AGE

Word Count: 3,915 / 5,000 words

Figures and Tables: 8 / 10

48 **Abstract** (250 / 250 words)

49 ***Purpose***

50 Relaxation correction is crucial for accurately estimating metabolite concentrations measured
51 using *in vivo* magnetic resonance spectroscopy (MRS). However, the majority of MRS
52 quantification routines assume that relaxation values remain constant across the lifespan,
53 despite prior evidence of T_2 changes with aging for multiple of the major metabolites. Here, we
54 comprehensively investigate correlations between T_2 and age in a large, multi-site cohort.

55 ***Methods***

56 We recruited approximately 10 male and 10 female participants from each decade of life: 18-29,
57 30-39, 40-49, 50-59, and 60+ years old ($n=101$ total). We collected PRESS data at 8 TEs (30,
58 50, 74, 101, 135, 179, 241, and 350 ms) from voxels placed in white-matter-rich centrum
59 semiovale (CSO) and gray-matter-rich posterior cingulate cortex (PCC). We quantified
60 metabolite amplitudes using Osprey and fit exponential decay curves to estimate T_2 .

61 ***Results***

62 Older age was correlated with shorter T_2 for tNAA, tCr_{3.0}, tCr_{3.9}, tCho, Glx, and tissue water in
63 CSO and PCC; $r_s = -0.21$ to -0.65 , all $p < 0.05$, FDR-corrected for multiple comparisons. These
64 associations remained statistically significant when controlling for cortical atrophy. T_2 values did
65 not differ across the adult lifespan for ml. By region, T_2 values were longer in the CSO for tNAA,
66 tCr_{3.0}, tCr_{3.9}, Glx, and tissue water and longer in the PCC for tCho and ml.

67 ***Conclusion***

68 These findings underscore the importance of considering metabolite T_2 changes with aging in
69 MRS quantification. We suggest that future 3T work utilize the equations presented here to
70 estimate age-specific T_2 values instead of relying on uniform default values.

71

72 **Keywords:** T_2 relaxation times, TE series, magnetic resonance spectroscopy (MRS),

73 metabolites, healthy aging

74 **1. Introduction**

75 Understanding brain changes across the healthy adult lifespan is critical for preserving
76 brain health in the quickly aging global population and uncovering possible mechanisms of age-
77 related neurological disease. Proton magnetic resonance spectroscopy (^1H MRS) is the only
78 methodology that allows non-invasive measurements of endogenous brain metabolite
79 concentrations. However, MRS data are often acquired at echo times (TEs) that are non-
80 negligible compared to metabolite transverse relaxation rates (T_2). This results in T_2 -weighting
81 of the signal, such that metabolite amplitude changes associated with normal aging might be
82 caused by changes in relaxation but misinterpreted as changes in metabolite concentration.
83 This confound exists even for short-TE MRS, but is particularly a concern for *J*-difference-edited
84 MRS¹, which relies on TEs of >65 ms (constrained by the duration of frequency-selective editing
85 pulses and the J-evolution of target metabolites). Thus, recent consensus¹⁻³ suggests that it is
86 critical to address the confound of T_2 relaxation (including for reference signals), particularly in
87 studies of aging and neurodegeneration. However, despite this, most MRS quantification
88 procedures (likely incorrectly) use static reference values, which assume that metabolite T_2
89 relaxation remains constant across the adult lifespan.

90 Prior work has reported varied relationships between age and T_2 , primarily for the singlet
91 resonances total *N*-acetyl aspartate (tNAA), creatine (tCr), and choline (tCho). A majority of prior
92 work at 3 and 4 T has reported shorter metabolite T_2 s with older age both for metabolites⁴⁻⁷ and
93 tissue water^{4,7}. A few studies^{8,9} at 1.5 T have reported the opposite effect of longer metabolite
94 T_2 s with older age; however, one of these studies⁹ was complicated by overlap among water
95 and metabolite signals, and the other⁸ examined only the frontal lobe and included only males in
96 the sample. One study¹⁰, also at 1.5 T, found longer NAA T_2 in the centrum semiovale of older
97 adults; however, this study utilized a linewidth-based approach which has not been validated or
98 used again since publication in 2005. With the exception of work by Brooks and colleagues⁸,
99 each of these prior studies involved comparison of discrete age groups (young versus older

100 adults) rather than continuous sampling across the adult lifespan, and each used small sample
101 sizes (all $n < 20$ per age group, with the exception of work by Deelchand and colleagues⁴ which
102 included 32 young and 26 older adults). Therefore, in the present study, we leveraged a large,
103 multi-site cohort in order to more comprehensively investigate whether metabolite and tissue
104 water T_2 values differ across the normal adult lifespan, and to provide statistical models for
105 calculating age-specific T_2 values for future integration into MRS quantification procedures.

106

107

108 **2. Methods**

109 **2.1 Participants**

110 101 healthy adults provided written informed consent to participate at one of two sites:
111 the Johns Hopkins University School of Medicine ($n = 51$) and the University of Florida ($n = 50$).
112 The sample included approximately 10 females and 10 males from each of the following
113 decades: 18–29, 30–39, 40–49, 50–59, and 60+ years (Table 1). The Johns Hopkins University
114 and University of Florida Institutional Review Boards approved all study procedures.
115 Participants first completed the Montreal Cognitive Assessment (MoCA)¹¹, followed by a 1-hour
116 MRI protocol. Of note, four individuals scored below the cut-off score of 23 out of 30 (i.e.,
117 indicative of possible mild cognitive impairment¹²). However, MoCA score was not an *a priori*
118 exclusion criterion for this study. Moreover, each of these individuals scored 22 (just below the
119 cut-off), and 3 of these 4 reported that English was not their primary language which can
120 negatively impact MoCA performance¹³ (and it was not feasible to conduct the MoCA in a
121 language other than English). Therefore, we presumed that cognitive impairment was not likely
122 and opted to retain these individuals in the cohort and statistical analyses.

123

124

125

126

127


128 **Table 1.** Participant Demographics

Variable	18-29 years	30-39 years	40-49 years	50-59 years	60+ years
Sex, #	10 F, 13 M	10 F, 10 M	10 F, 10 M	9 F, 9 M	11 F, 9 M
Age, Mean (SD), [Min, Max], years	24.2 (3.3) [18.7, 29.8]	35.0 (2.9) [30.3, 39.9]	44.2 (3.0) [40.0, 49.2]	55.0 (2.9) [50.2, 59.8]	67.5 (4.1) [60.8, 75.4]
MoCA, Mean (SD) ^a [Min, Max]	27.9 (2.0) [23, 30]	28.0 (2.3) [23, 30]	27.6 (2.5) [22, 30]	26.3 (1.8) [23, 29]	27.7 (2.5) [22, 30]

130
131 ^a One point was added to the MoCA score for $n = 9$, as these individuals reported having completed 12
132 years of education or less¹¹.

133
134
135 **2.2 MRS Acquisition**

136 All scans were performed using a 32-channel head coil on either the Johns Hopkins
137 University 3 T Philips dStream Ingenia Elition MRI scanner or the University of Florida 3 T
138 Philips MR7700 MRI scanner. For voxel positioning, we first collected a T_1 -weighted structural
139 MRI scan using the following parameters: MPRAGE, TR/TE 2000 ms/2 ms, flip angle 8°, slice
140 thickness 1.0 mm, 150 slices, voxel size 1 mm³ isotropic, total time 2 min 46 sec. Next, we
141 acquired TE series data from two 30 x 26 x 26 mm³ voxels: the white matter (WM) rich centrum
142 semiovale (CSO) and the gray matter (GM) rich posterior cingulate cortex (PCC; Figure 1).
143 Scan parameters for the TE series included: PRESS localization, TR 2000 ms, 8 logarithmically-
144 spaced TEs 30, 50, 74, 101, 135, 179, 241, and 350 ms, 24 transients per TE sampled at 2000
145 Hz with 1024 points, and CHESS water suppression (115 Hz bandwidth). Within each series,
146 the TE steps were neither interleaved nor randomized. We also collected a separate series of
147 unsuppressed water reference data at each of the 8 TEs with the same parameters, but with 2
148 transients per TE and no water suppression. Of note, these voxel sizes and locations were
149 selected to match those collected in our recent cohort of short-TE PRESS metabolite data in
150 102 individuals ranging from their 20s to their 60s¹⁴.



151
152
153
154
155
156
157

Figure 1. Voxel Placement. TE series data were acquired from the centrum semiovale (CSO) and posterior cingulate cortex (PCC). Each participant's native space binary voxel mask for their CSO and PCC voxels was normalized to standard (MNI) space and overlaid onto the spm152 template. Warmer colors indicate areas of greater overlap between participants (color bar = number of subjects overlapped).

158 2.2 MRS Data Processing

159 MRS data were analyzed within MATLAB R2021b using the open-source analysis
160 toolbox Osprey (v2.5.0; <https://github.com/schorschinho/osprey/>)¹⁵. All analysis procedures
161 followed consensus-recommended guidelines^{1,3}. Briefly, analysis steps included: loading the
162 vendor-native raw data (which had already been coil-combined, eddy-current-corrected, and
163 averaged on the scanner at the time of data collection), removing the residual water signal using
164 a Hankel singular value decomposition (HSVD) filter¹⁶, and modeling the metabolite peaks at
165 each TE separately as described previously^{15,17} using TE-specific custom basis sets. The basis
166 sets were simulated by the MRSCloud tool¹⁸ (<https://braingps.mricloud.org/mrs-cloud>).
167 MRSCloud using a localized 2D density-matrix simulation of a 101 x 101 spatial grid (voxel size
168 30 x 30 x 30 mm³; field of view 45 x 45 x 45 mm³) and vendor-specific refocusing pulse shape,
169 duration, and sequence timings based on the MATLAB simulation toolbox FID-A¹⁹. The basis
170 sets consisted of 18 basis functions: ascorbate (Asc), aspartate (Asp), creatine (Cr), negative
171 creatine methylene (-CrCH₂), gamma-aminobutyric acid (GABA), glycerophosphocholine (GPC),

172 glutathione (GSH), glutamine (Gln), glutamate (Glu), lactate (Lac), myo-inositol (ml), *N*-acetyl
173 aspartate (NAA), *N*-acetyl aspartyl glutamate (NAAG), phosphocholine (PCh), phosphocreatine
174 (PCr), phosphoethanolamine (PE), scyllo-inositol (sl), and taurine (Tau), as well as 5
175 macromolecule signals (MM09, MM12, MM14, MM17, MM20) and 3 lipid signals (Lip09, Lip13,
176 Lip20) included as parameterized Gaussian functions¹⁷.

177 We extracted amplitudes for 6 metabolites of interest: tNAA, tCho, tCr_{3.0} (Cr + PCr),
178 tCr_{3.9} (Cr + PCr - (-CrCH₂)), ml, and Glx (Glu + Gln). We multiplied each metabolite amplitude by
179 Osprey's internal *MRSCont.fit.scale* factor for each TE and participant to make the metabolite
180 amplitudes directly comparable across TEs. This scaling factor is applied to the data to ensure
181 an optimal dynamic range between the data and basis set during modeling. It is defined as the
182 ratio of the maximum of the real part of the data and the basis set in the model range. Next, we
183 used *lsqcurvefit* in MATLAB to fit monoexponential T₂ decay functions to the TE series
184 metabolite amplitudes (Equation 1) in order to obtain the T₂ decay constant and an R² value of
185 model fit for each participant for each metabolite.

$$186 \quad y_i = A_i * e^{\left(-\frac{TE}{T_{2i}}\right)} \quad [1]$$

187 In Equation 1, y_i represents the metabolite amplitude, A_i is a scaling constant, and T_{2i} is the
188 relaxation time to be calculated for the i^{th} subject. Lastly, we created a binary mask of the two
189 MRS voxels in subject space, co-registered these masks to each participant's T₁-weighted
190 structural scan, and segmented the structural scans using SPM12²⁰, in order to calculate the
191 volume fractions of white matter (fWM), gray matter (fGM), and cerebrospinal fluid (fCSF) in
192 each participant's voxels in subject space (for use in statistical models to control for cortical
193 atrophy and for estimation of tissue water T₂).

194 We then repeated a similar procedure for tissue water. To estimate the water
195 amplitudes, the unsuppressed water data at each TE was modeled using a linear combination

196 model with a simulated water signal¹⁸. We used MATLAB's *lsqcurvefit* to fit a biexponential
197 decay function (Equation 2) to obtain tissue water T_2 and R^2 values for each participant.

$$198 \quad y_i = A_i * e^{\left(-\frac{TE}{T_{2wi,tissue}}\right)} * 0.4211 * (1 - fCSF) + A_i * e^{\left(-\frac{TE}{T_{2wi,CSF}}\right)} * 0.5789 * fCSF \quad [2]$$

199 In Equation 2, y_i represents the water amplitude, A_i is a scaling constant, $T_{2wi,tissue}$ is the tissue
200 water relaxation time, and $T_{2wi,CSF}$ is the CSF water relaxation time to be calculated for the i^{th}
201 subject. $fCSF$ is the fraction of CSF within the voxel for the i^{th} subject; 0.4211 weights the first
202 term by the approximate molal concentration of water for non-CSF tissue ($40/(40+55)$), and
203 0.5789 weights the second term by the approximate molal concentration of water for CSF
204 ($55/(40+55)$). The A_i and $T_{2wi,tissue}$ terms were unconstrained, and the $T_{2wi,CSF}$ term was
205 constrained to the range of 50–3000 ms^{21–23}. A data acquisition error occurred at the University
206 of Florida site for the water data; therefore, we included only the Johns Hopkins University
207 participants ($n = 51$) in statistical analyses of the water T_2 data.

208 **2.3 Statistical Analyses**

209 We conducted all statistical analyses using R 4.3.2²⁴ within RStudio²⁵. First, we
210 calculated descriptive statistics (mean, standard deviation) by age group for the T_2 values for
211 each of the 6 metabolites of interest and tissue water. Next, we examined the correlation
212 between T_2 and age for each metabolite and voxel separately. As multiple variables did not
213 satisfy the Pearson correlation normality assumption (Shapiro test $p < 0.05$), we instead report
214 nonparametric Spearman correlations. To account for multiple comparisons, we applied the
215 Benjamini-Hochberg false discovery rate (FDR) correction to the p -values for each voxel²⁶.
216 Secondly, we ran a series of linear models, setting each metabolite T_2 as the outcome variable
217 and age as the predictor: $T_2 = \beta_0 + \beta_1 * (\text{Age} - 30)$. We centered age around 30 years, so that the
218 intercept (β_0) from this model would represent the predicted metabolite T_2 value at 30 years old,
219 and the slope (β_1) would represent the change in T_2 for each year of age. The aim of this model
220 was to provide an equation to calculate predicted T_2 value for a given metabolite given the age

221 of a participant. As a follow-up analysis, we reran each of these linear models controlling for the
222 potential effects of cortical atrophy with aging: $T_2 = \beta_0 + \beta_1*(Age-30) + \beta_2*Tissue$. As in our
223 recent work examining metabolite T_1 changes with aging²⁷, we calculated cortical atrophy as the
224 relative tissue fraction within the voxel, $fGM / (fWM + fGM)$. The purpose of this follow-up model
225 was to ensure that cortical atrophy effects were not a major contributing factor to the observed
226 T_2 relationships with age.

227 In addition, we conducted a series of paired t-tests (followed by FDR correction of the p -
228 values²⁶) to examine differences in metabolite T_2 values between the CSO and PCC voxels. We
229 also computed one linear mixed effects model per metabolite in which we set T_2 (across both
230 the CSO and PCC voxels) as the outcome variable, age, voxel, and the interaction of age with
231 voxel as the predictors, and a random intercept (u_i) for each subject: $T_2 = \beta_0 + \beta_1*(Age-30) +$
232 $\beta_2*Voxel + \beta_3*(Age-30)*Voxel + u_i$. The primary aim of this model was to test for any Age*Voxel
233 interaction effects (i.e., whether the age slope differed by brain region in any cases). The linear
234 mixed effects model and random subject intercepts were necessary because this modeling
235 approach structured the data as 'repeated measures' in which each participant had two
236 measurements (CSO T_2 and PCC T_2).

237


238

239 3. Results

240 3.1 Data Quality

241 Creatine (Cr) linewidths were well within the range of consensus-recommended
242 standards (i.e., < 13 Hz for 3 T^3) for all spectra except one individual's CSO voxel (33-year-old
243 male, Cr linewidth = 14.1 Hz). In addition, for one participant (19-year-old male), the PCC voxel
244 was mistakenly positioned at the wrong location. Thus, these datasets (1 CSO and 1 PCC) were
245 excluded before any statistical analyses. Additional consensus-recommended data quality
246 metrics are presented in Appendix A. Example single-subject spectra at each TE and decay

247 functions for each metabolite are presented in Figure 2. The mean R^2 value across the whole
248 cohort for the goodness of fit of the T_2 decay model was ≥ 0.80 for each of the 6 metabolites of
249 interest and tissue water. Table 2 presents descriptive statistics by age group for the T_2 values.



250

251 **Figure 2. Single-Subject Example Spectra and CSO T_2 Decay.** **A** PRESS spectra for each of the 8 TEs
252 for the CSO (left) and PCC (right) voxels for a representative subject (48-year-old female). This
253 representative subject was determined by averaging the R^2 values of model fit across the 6 metabolites
254 and tissue water for each person in the Johns Hopkins cohort (as water data were unavailable for
255 University of Florida subjects) and then taking the group median of this average R^2 value. **B** Example T_2
256 decay plots for the 6 metabolites and tissue water from the CSO voxel for the same representative
257 subject. Blue points represent the metabolite amplitude at each TE, and the dark blue line represents the
258 calculated T_2 decay curve.
259

260 **Table 2.** T₂ Descriptive Statistics by Age Group
261

CSO Voxel					
Metabolite	18-29 years	30-39 years	40-49 years	50-59 years	60+ years
	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)
tNAA	298.9 (22.5)	283.8 (24.3)	267.9 (24.2)	267.9 (24.6)	260.6 (23.8)
tCr _{3.0}	159.5 (10.6)	153.0 (8.8)	147.7 (11.5)	148.3 (8.9)	147.9 (8.6)
tCr _{3.9}	145.0 (10.7)	133.9 (16.2)	133.0 (10.3)	133.9 (8.6)	132.9 (9.3)
tCho	230.1 (18.6)	216.3 (24.4)	203.0 (19.7)	204.5 (17.7)	207.8 (19.7)
ml	146.7 (14.0)	141.5 (17.2)	132.7 (11.7)	144.8 (16.0)	140.6 (19.0)
Glx	206.1 (40.6)	213.7 (36.7)	186.3 (29.6)	195.6 (42.1)	181.5 (30.3)
Tissue Water ^a	64.8 (2.1)	64.1 (2.3)	62.7 (2.6)	62.5 (3.1)	62.4 (2.5)
PCC Voxel					
Metabolite	18-29 years	30-39 years	40-49 years	50-59 years	60+ years
	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)
tNAA	255.2 (22.6)	237.1 (12.8)	224.0 (15.3)	221.1 (16.7)	215.6 (14.7)
tCr _{3.0}	155.5 (8.9)	149.6 (7.8)	144 (8.6)	145.3 (5.8)	145.8 (8.5)
tCr _{3.9}	131.1 (9.1)	126.4 (5.2)	125.8 (9.6)	123.6 (7.4)	127.6 (10.0)
tCho	258.2 (25.2)	240.3 (13.3)	221 (15.9)	224.2 (20.2)	228.0 (20.3)
ml	166.8 (15.0)	157.1 (13.7)	157.5 (14.2)	158.0 (13.6)	159.5 (16.3)
Glx	166.8 (19.2)	156.7 (21.6)	164.8 (29.3)	162.9 (23.8)	147.6 (31.2)
Tissue Water ^a	54.8 (4.0)	55.2 (2.5)	52.1 (2.5)	49.7 (5.9)	50.7 (2.7)

Note. This table lists T₂ values in ms for the 6 metabolites and tissue water.

^a Tissue water includes only the *n* = 51 Johns Hopkins subjects.

262 3.2 T₂ Relationships with Age

263 Older age was significantly correlated with shorter T₂ values for tNAA, tCr_{3.0}, tCr_{3.9}, tCho,
264
265 Glx, and tissue water in both the CSO and PCC; Spearman *r* = -0.21 to -0.65, *p* < 0.05, FDR-
266 corrected for multiple comparisons (Figure 3; Table 3). Age was most strongly correlated with
267 tNAA T₂. Age did not correlate with ml T₂ for either voxel.
268

273

274

275

276

277
278


Table 3. T₂ Correlations with Age

Metabolite	CSO		PCC	
	r _s	p _{FDR-corr}	r _s	p _{FDR-corr}
tNAA	-0.46	< 0.001***	-0.65	< 0.001***
tCr _{3.0}	-0.37	< 0.001***	-0.43	< 0.001***
tCr _{3.9}	-0.34	0.001**	-0.21	0.047*
tCho	-0.38	< 0.001***	-0.51	< 0.001***
ml	-0.07	0.477	-0.17	0.095
Glx	-0.34	0.001**	-0.24	0.022*
Tissue Water ^a	-0.30	0.035*	-0.46	0.001**

279
280
281
282
283
284

Note. This table presents the Spearman r values and FDR-corrected p-values for the correlation of age with metabolite T₂ in the CSO and PCC voxels separately; *p<0.05, **p<0.01, ***p<0.001.

^a Tissue water includes only the n = 51 Johns Hopkins subjects.



285
286
287
288

Figure 3. Metabolite T₂ Correlations with Age. T₂ correlations with age are shown for the CSO (above, blue) and PCC (below, orange). Each point represents one participant. The bottom right corner of each

289 plot indicates the Spearman correlation coefficient (r_s) and statistical significance of the FDR-corrected p -
290 value for the correlation, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. The gray line and shading represent the linear
291 model and 95% confidence interval for the model using age to predict T_2 (produced using the
292 *geom_smooth* function in R).

293
294
295 Next, we fit linear models to predict T_2 using age for each metabolite and voxel
296 combination: $T_2 = \beta_0 + \beta_1 \cdot (\text{Age} - 30)$; Table 4. As we centered age around 30 years old, the
297 intercept (β_0) represents the predicted T_2 value for each metabolite at 30 years of age (as
298 opposed to age 0 which would represent an unhelpful extrapolation). The slope (β_1) represents
299 the change in the predicted value of T_2 for each year of life. For example, for tNAA in the CSO,
300 the predicted T_2 value for an individual age 30 years would be: $T_2 = 288.27 + (30 - 30) \cdot -0.81 =$
301 288.27 ms, while the predicted T_2 value for an individual age 50 years would be $T_2 = 288.27 +$
302 $(50 - 30) \cdot -0.81 = 272.07$ ms. (Note that these predicted T_2 values also correspond to the gray
303 linear model lines plotted in Figure 3). The slope and intercept values listed in Table 4 can thus
304 be utilized to calculate a predicted T_2 for any age in a WM- or GM-rich voxel. Table 4 only
305 includes slopes for the metabolites which were significantly correlated with age.

306

307 **Table 4. Model Coefficients for Estimating T_2**

308

Metabolite	CSO		PCC	
	Intercept	Slope (β_1)	Intercept	Slope (β_1)
tNAA	288.27	-0.81	244.35	-0.89
tCr _{3.0}	155.21	-0.25	151.67	-0.24
tCr _{3.9}	139.88	-0.26	128.53	-0.10
tCho	220.32	-0.51	245.66	-0.73
ml	142.39		162.13	
Glx	206.54	-0.68	165.20	-0.37
Tissue Water ^a	64.11	-0.05	54.38	-0.12

309

310 *Note.* This table presents the intercept and slope (β_1) values for the linear model using age to predict T_2
311 values: $T_2 = \beta_0 + \beta_1 \cdot (\text{Age} - 30)$. Slope is listed only for the metabolites which were significantly correlated with
312 age. As Age is centered around 30 years in the equation, the intercept (β_0) represents the predicted T_2 value
313 for each metabolite at Age = 30 years. The slope (β_1) represents the change in the predicted value of T_2 for
314 each 1-year increase in age beyond 30. This model can be used in future work to predict a T_2 value for a
315 given age for these metabolites.

316

317

318

319

^a Tissue water includes only the $n = 51$ Johns Hopkins subjects.


320

321 Older age was significantly correlated with greater cortical atrophy (calculated as fGM /
(fWM + fGM)) in the PCC ($r_s = -0.25$; $p = 0.010$) but not the CSO ($r_s = -0.04$; $p = 0.680$). As a

322 follow-up to the linear models presented in Table 4, we reran each model controlling for cortical
323 atrophy with aging: $T_2 = \beta_0 + \beta_1*(Age-30) + \beta_2*Tissue$ (see Supplementary Table B1). Including
324 this metric of cortical atrophy in the model did not change the statistical significance of any T_2
325 relationships with age, with the exception of $tCr_{3.9}$ in the PCC (for which the age- T_2 relationship
326 became non-significant, $p = 0.094$). Independent of the associations between age and T_2 ,
327 greater cortical atrophy was significantly associated with longer metabolite T_2 values for tNAA,
328 $tCr_{3.0}$, and $tCr_{3.9}$ (CSO only), as well as ml and tissue water (CSO and PCC).

329 3.2 T_2 Differences by Voxel

330 Paired t-tests revealed differences in T_2 values by voxel for all metabolites (as shown in
331 Figure 4). T_2 values were higher in the CSO than in the PCC for tNAA, $tCr_{3.0}$, $tCr_{3.9}$, Glx, and
332 tissue water, and lower in the CSO for tCho and ml.



333 **Figure 4. Metabolite T_2 Differences by Voxel.** T_2 differences by voxel are shown for the CSO (blue) and
334 PCC (orange). Each point represents one participant. The asterisks indicate the statistical significance of
335 the FDR-corrected p -value for the paired t-test, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.
336
337

338 As a follow-up analysis, we computed one linear mixed effects model per metabolite (across
339 both the CSO and PCC) to test whether the age slope differed by brain region for any
340 metabolites or tissue water. The Age*Voxel interaction was significant only for tissue water

341 ($p=0.007$), indicating that, in all but one case, the relationship of age with T_2 did not differ based
342 on brain region (Supplementary Table B2). However, for tissue water, the relationship of age
343 with T_2 was stronger for the PCC than the CSO.

344

345 **4. Discussion**

346 Here we present the largest analysis to date examining metabolite and tissue water T_2
347 changes across the healthy adult lifespan. Among 101 adults ages 18-75 and across two sites,
348 metabolite and tissue water T_2 values in both the CSO and PCC were generally significantly
349 shortened with age, even when controlling for age-related cortical atrophy. Moreover, T_2 values
350 were longer in the CSO, with the exception of tCho and ml which exhibited longer T_2 in the
351 PCC. Taken together, these results align with the majority of prior work which also reported T_2
352 declines with normal aging (but in much smaller cohorts). Moreover, the finding of T_2 differences
353 based on age and brain region highlights the importance of measuring subject-level T_2 during
354 data acquisition or employing estimation methods (such as the statistical models provided here)
355 for calculating age- and region-appropriate T_2 values.

356 Older age was correlated with shorter metabolite T_2 values for tNAA, tCr_{3.0}, tCr_{3.9}, tCho,
357 Glx, and tissue water in both the CSO and PCC. This aligns with most prior research in smaller
358 samples which similarly found shorter tNAA, tCr, tCho, and tissue water T_2 s with older age⁴⁻⁷.
359 As also seen in these prior studies, we identified the strongest age association for tNAA. Most
360 prior reports did not examine Glx. Deelchand and colleagues (2020) reported reduced ml T_2 in
361 CSO and PCC in older age, whereas we did not find an association between ml T_2 and age.
362 However, it should be noted that Deelchand and colleagues⁴ compared two age groups (rather
363 than treating age as a continuous variable), and their older cohort (ages 70-83 years) extended
364 beyond our upper age range.

365 The specific mechanisms underlying these observed T_2 changes with aging remain
366 unclear. With the exception of tCr_{3.9} in the PCC, each of the identified T_2 associations with age

367 remained statistically significant when controlling for cortical atrophy, suggesting that age-
368 related atrophy is not a major factor in these findings. Instead, as metabolites are largely
369 intracellular (glial or neuronal)²⁸, their T_2 relaxation times are likely influenced by changes in the
370 cellular microenvironment⁴, i.e. cellular morphology, metabolism, or myelination^{4,7}. It is well
371 established that neurons undergo morphological changes during aging—such as reduction in
372 soma size and loss or regression of dendrites and dendritic spines²⁹— alongside a parallel
373 metabolic shift in astrocytes associated with increased neuroinflammatory response and
374 changes in oxidative metabolism^{30,31}. Furthermore, degeneration of myelin sheath³² and loss of
375 axonal fiber³² with advancing age, accompanied by debris (e.g., protein aggregates) and
376 degraded myelin accumulation^{33,34} reported in white matter and further supported by *in vivo*
377 diffusion tensor imaging^{35,36}.

378 The observed T_2 changes could also be influenced by the gradual deposition of iron,
379 particularly Fe^{3+} , in the brain with aging. Although iron is present in the brain in multiple forms,
380 the intracellular non-heme iron (i.e., ferritin) in tissue is thought to cause dephasing of the proton
381 spins and thus a faster T_2 decay³⁷. Several studies observed a strong linear correlation between
382 iron concentrations and transverse relaxation (R_2)³⁸ values both *in vivo* and in post-mortem
383 healthy and Alzheimer's disease brain tissue³⁷, suggesting that faster T_2 relaxation is related to
384 age-related iron deposition³⁹. Whilst the precise contribution of each of these mechanisms is
385 unclear, the observed age relationships suggest that T_2 measurements are sensitive to various
386 parallel changes in the cellular environment⁷.

387 In this dataset, T_2 relaxation times were predominantly longer for tNAA, tCr_{3.0}, tCr_{3.9}, Glx,
388 and tissue water in the WM-rich CSO, whereas tCho and ml exhibited longer T_2 in the GM-rich
389 PCC. There is relatively limited literature considering GM/WM differences in metabolite T_2 , and
390 this prior work differs in voxel location, cohort, acquisition and quantification methodology, and
391 statistical approach. Of the seven references we identified^{6,40–45}, five reported longer T_2 for NAA
392 in WM as we did^{6,40–42,45}, while one revealed no significant tissue effect⁴³ and one showed the

393 reverse effect⁴⁴. For tCr_{3,0}, three references found our result of longer T₂ in WM^{6,41,42}, three
394 showed no difference^{40,43,45}, and the same study showed the reverse effect⁴⁴. Only a few studies
395 have measured T₂s of tCr_{3,9} or Glx. For tCr_{3,9}, one paper showed longer T₂s in WM⁴⁵ (as we
396 found) and one no difference⁴²; for Glx, one study that separated Glx as Glu and Gln with J-
397 PRESS found no differences by tissue type in the major component, Glu⁴². For tCho, four
398 studies found no difference^{40,41,43,45}, two found longer T₂ in GM^{42,44} (as we did), and one longer
399 T₂ in WM⁶. T₂ of ml remains less investigated, but the two studies that measured ml T₂ also
400 found longer T₂ in GM^{42,44}. For tissue water, GM is generally found to have longer T₂ values than
401 WM in multi-echo MRI experiments^{46–48}, although the extent to which CSF confounds this result
402 depends on resolution. Regional T₂ differences may relate to greater micro- and macro-
403 structural organization in myelinated WM compared to GM⁴⁹; however, further work is needed to
404 fully understand the mechanisms that govern metabolite T₂ relaxation.

405 We recently performed a meta-regression analysis of 75 manuscripts⁵⁰ containing 629
406 unique values to derive a general predictive T₂ model, with linear factors for: metabolite, field
407 strength, species, tissue, pulse sequence, and Carr-Purcell Meiboom-Gill filter. The average
408 bias between the (30-year-old intercept) values reported in the present study and the model
409 predicted values was +9 ms (i.e., on average the model predicts shorter T₂s than measured
410 here). The average absolute difference was 23 ms which is smaller than the average absolute
411 difference between the predicted model and the T₂ training dataset (42 ms). On this basis, we
412 assert that our results are consistent with the diverse T₂ literature.

413 2D modeling of interrelated MRS data has recently gained interest in the MRS
414 community^{51–53}. Most notably, it was found that 2D modeling of synthetic multi-TE MRS data
415 with overlapping peaks led to improved precision due to improved model parsimony achieved
416 through reparametrization⁵¹. Applying 2D modeling to our *in vivo* datasets may improve the T₂
417 estimation of the metabolites reported here and could potentially allow for the T₂ estimation of
418 additional low-SNR metabolites. However, it will also require careful reparameterization of the T₂

419 relaxation constants, lineshape estimates, and baseline terms, which will be part of future
420 studies.

421 There are several limitations to this work. First, we acknowledge that our T_2
422 measurement here is a complex mix of pure T_2 and some inhomogeneous broadening factors
423 that are not fully refocused by the two PRESS spin echoes. The goal of the present work was to
424 improve the accuracy of T_2 relaxation correction in quantification procedures by understanding
425 age effects on our measure of T_2 (rather than to accurately measure pure T_2). Second, future
426 work could expand upon the age range to include those younger than 18 and older than 70
427 years, as well as targeting both normal and pathological aging (e.g., Alzheimer's and other
428 neurodegenerative diseases). Given the potential of T_2 to reflect both micro- and
429 macrostructural organization, the measure may show utility as an early indicator of these
430 changes, as suggested by Kirov and Tal⁵⁴. Though this was a large cohort with systematic
431 recruitment across the adult lifespan, we only enrolled a few individuals older than age 70 years
432 (the timeframe at which aging effects drastically accelerate). Lastly, we were limited to collecting
433 only two voxels (WM-rich CSO and GM-rich PCC); however, prior evidence suggests that
434 neurochemical changes with aging are highly region-dependent⁵⁵, and therefore future work
435 might consider probing T_2 changes in other brain regions, or across the entire brain.

436

437 **5. Conclusions**

438 Consistent with prior literature, in a large multi-site cohort sampled systematically across
439 the adult lifespan, we identified a clear age-related decrease in T_2 for multiple metabolites and
440 tissue water, as well as differences in T_2 between the WM-rich CSO and GM-rich PCC.
441 Together, these findings highlight potential changes in the brain's cellular microenvironment with
442 normal aging and underscore the critical importance of considering metabolite T_2 differences
443 across the adult lifespan in MRS quantification procedures. We suggest that future MRS work

T2 CHANGES WITH AGE

19

- 444 leverage the models presented here to estimate age- and region-specific T_2 values instead of
- 445 relying on uniform default values.

446 **Competing Interests**

447 All authors declare that they have no competing interests.

448

449 **Author Contributions**

450 KH processed all data, conducted all statistical analyses, prepared all figures and supplemental
451 material, and prepared the manuscript. SM contributed to protocol development, manuscript
452 writing and led all revisions of the manuscript. HZ contributed to MRS data processing, and
453 developed Osprey code for the analysis. YS and EC made significant contributions to data
454 collection. CDJ generated the spectra figure and contributed to interpretation of results. AG, DS,
455 and GS contributed to interpretation of results and drafted parts of the Discussion. VY reviewed
456 all structural scans to assess data quality and check for incidental findings. SH set up the scan
457 protocol and oversaw data quality control. GO, EP, and RAE designed the project and led
458 interpretation of the results. All authors participated in revision of the manuscript.

459

460 **Funding**

461 This work was supported by grants from the National Institute on Aging (K00 AG068440 to KH,
462 R00 AG062230 to GO, and K99 AG080084 to HZ) and grants from the National Institute of
463 Biomedical Imaging and Bioengineering (R21 EB033516 to GO, R01 EB023963 to RE, R01
464 EB016089 to RE, and P41 EB031771).

465

466 **Acknowledgements**

467 The authors also wish to thank all of the participants who volunteered their time, as well as
468 support staff at both MRI centers, without whom this project would not have been possible.

469 **References**

- 470
- 471 1. Choi IY, Andronesi OC, Barker P, et al. Spectral editing in 1H magnetic resonance
472 spectroscopy: Experts' consensus recommendations. *NMR Biomed.* 2021;34(5):e4411.
- 473 2. Near J, Harris AD, Juchem C, et al. Preprocessing, analysis and quantification in single-
474 voxel magnetic resonance spectroscopy: experts' consensus recommendations. *NMR*
475 *Biomed.* 2021;34(5). doi:10.1002/nbm.4257
- 476 3. Wilson M, Andronesi O, Barker PB, et al. Methodological consensus on clinical proton MRS
477 of the brain: Review and recommendations. *Magn Reson Med.* 2019;82(2):527-550.
- 478 4. Deelchand DK, McCarten JR, Hemmy LS, Auerbach EJ, Eberly LE, Marjańska M. Changes
479 in the intracellular microenvironment in the aging human brain. *Neurobiol Aging.*
480 2020;95:168-175.
- 481 5. Jiru F, Skoch A, Wagnerova D, et al. The age dependence of T_2 relaxation times of N-
482 acetyl aspartate, creatine and choline in the human brain at 3 and 4T. *NMR Biomed.*
483 2016;29(3):284-292. doi:10.1002/nbm.3456
- 484 6. Kirov II, Fleysher L, Fleysher R, Patil V, Liu S, Gonen O. Age dependence of regional proton
485 metabolites T_2 relaxation times in the human brain at 3 T. *Magn Reson Med.*
486 2008;60(4):790-795. doi:10.1002/mrm.21715
- 487 7. Marjańska M, Emir UE, Deelchand DK, Terpstra M. Faster metabolite 1H transverse
488 relaxation in the elder human brain. *PloS One.* 2013;8(10):e77572.
- 489 8. Brooks JCW, Roberts N, Kemp GJ, Gosney MA, Lye M, Whitehouse GH. A Proton Magnetic
490 Resonance Spectroscopy Study of Age-related Changes in Frontal Lobe Metabolite
491 Concentrations. *Cereb Cortex.* 2001;11(7):598-605. doi:10.1093/cercor/11.7.598
- 492 9. Christiansen P, Toft P, Larsson HBW, Stubgaard M, Henriksen O. The concentration of N-
493 acetyl aspartate, creatine + phosphocreatine, and choline in different parts of the brain in
494 adulthood and senium. *Magn Reson Imaging.* 1993;11(6):799-806. doi:10.1016/0730-
495 725X(93)90197-L
- 496 10. Kreis R, Slotboom J, Hofmann L, Boesch C. Integrated data acquisition and processing to
497 determine metabolite contents, relaxation times, and macromolecule baseline in single
498 examinations of individual subjects. *Magn Reson Med.* 2005;54(4):761-768.
499 doi:10.1002/mrm.20673
- 500 11. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA:
501 A Brief Screening Tool For Mild Cognitive Impairment. *J Am Geriatr Soc.* 2005;53(4):695-
502 699. doi:10.1111/j.1532-5415.2005.53221.x
- 503 12. Carson N, Leach L, Murphy KJ. A re-examination of Montreal Cognitive Assessment
504 (MoCA) cutoff scores. *Int J Geriatr Psychiatry.* 2018;33(2):379-388. doi:10.1002/gps.4756
- 505 13. Ng KP, Chiew HJ, Lim L, Rosa-Neto P, Kandiah N, Gauthier S. The influence of language
506 and culture on cognitive assessment tools in the diagnosis of early cognitive impairment and

- 507 dementia. *Expert Rev Neurother*. 2018;18(11):859-869.
508 doi:10.1080/14737175.2018.1532792
- 509 14. Gong T, Hui SCN, Zöllner HJ, et al. Neurometabolic timecourse of healthy aging.
510 *NeuroImage*. 2022;264:119740. doi:10.1016/j.neuroimage.2022.119740
- 511 15. Oeltzschner G, Zöllner HJ, Hui SC, et al. Osprey: Open-source processing, reconstruction &
512 estimation of magnetic resonance spectroscopy data. *J Neurosci Methods*.
513 2020;343:108827.
- 514 16. Barkhuijsen H, De Beer R, Van Ormondt D. Improved algorithm for noniterative time-domain
515 model fitting to exponentially damped magnetic resonance signals. *J Magn Reson* 1969.
516 1987;73(3):553-557.
- 517 17. Zöllner HJ, Považan M, Hui SC, Tapper S, Edden RA, Oeltzschner G. Comparison of
518 different linear-combination modeling algorithms for short-TE proton spectra. *NMR Biomed*.
519 2021;34(4):e4482.
- 520 18. Hui SCN, Saleh MG, Zöllner HJ, et al. MRSCLOUD : A cloud-based MRS tool for basis set
521 simulation. *Magn Reson Med*. 2022;88(5):1994-2004. doi:10.1002/mrm.29370
- 522 19. Simpson R, Devenyi GA, Jezzard P, Hennessy TJ, Near J. Advanced processing and
523 simulation of MRS data using the FID appliance (FID-A)—An open source, MATLAB -
524 based toolkit. *Magn Reson Med*. 2017;77(1):23-33. doi:10.1002/mrm.26091
- 525 20. Ashburner J, Barnes G, Chen CC, et al. SPM12 manual. *Wellcome Trust Cent*
526 *Neuroimaging Lond UK*. 2014;2464:4.
- 527 21. Piechnik SK, Evans J, Bary LH, Wise RG, Jezzard P. Functional changes in CSF volume
528 estimated using measurement of water T_2 relaxation. *Magn Reson Med*. 2009;61(3):579-
529 586. doi:10.1002/mrm.21897
- 530 22. Daoust A, Dodd S, Nair G, et al. Transverse relaxation of cerebrospinal fluid depends on
531 glucose concentration. *Magn Reson Imaging*. 2017;44:72-81. doi:10.1016/j.mri.2017.08.001
- 532 23. Spijkerman JM, Petersen ET, Hendrikse J, Luijten P, Zwanenburg JJM. T 2 mapping of
533 cerebrospinal fluid: 3 T versus 7 T. *Magn Reson Mater Phys Biol Med*. 2018;31(3):415-424.
534 doi:10.1007/s10334-017-0659-3
- 535 24. R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for
536 Statistical Computing; 2021. <https://www.R-project.org/>
- 537 25. RStudio Team. *RStudio: Integrated Development Environment for R*. RStudio, PBC; 2021.
538 <http://www.rstudio.com/>
- 539 26. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful
540 Approach to Multiple Testing. *J R Stat Soc Ser B Methodol*. 1995;57(1):289-300.
541 doi:10.1111/j.2517-6161.1995.tb02031.x
- 542 27. Murali-Manohar S, Gudmundson AT, Hupfeld KE, et al. *Metabolite T_1 Relaxation Times*
543 *Differ across the Adult Lifespan*. *Neuroscience*; 2023. doi:10.1101/2023.01.06.522927

- 544 28. Ronen I, Valette J. Diffusion-Weighted Magnetic Resonance Spectroscopy. In: Harris RK,
545 Wasylishen RL, eds. *eMagRes*. John Wiley & Sons, Ltd; 2015:733-750.
546 doi:10.1002/9780470034590.emrstm1471
- 547 29. Dickstein DL, Kabaso D, Rocher AB, Luebke JI, Wearne SL, Hof PR. Changes in the
548 structural complexity of the aged brain. *Aging Cell*. 2007;6(3):275-284. doi:10.1111/j.1474-
549 9726.2007.00289.x
- 550 30. Verkerke M, Hol EM, Middeldorp J. Physiological and Pathological Ageing of Astrocytes in
551 the Human Brain. *Neurochem Res*. 2021;46(10):2662-2675. doi:10.1007/s11064-021-
552 03256-7
- 553 31. Jiang T, Cadenas E. Astrocytic metabolic and inflammatory changes as a function of age.
554 *Aging Cell*. 2014;13(6):1059-1067. doi:10.1111/accel.12268
- 555 32. Peters A. The effects of normal aging on myelin and nerve fibers: A review. *J Neurocytol*.
556 2002;31(8/9):581-593. doi:10.1023/A:1025731309829
- 557 33. Safaiyan S, Kannaiyan N, Snaidero N, et al. Age-related myelin degradation burdens the
558 clearance function of microglia during aging. *Nat Neurosci*. 2016;19(8):995-998.
559 doi:10.1038/nn.4325
- 560 34. Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of Cognitively Normal Elderly. *J*
561 *Neuropathol Exp Neurol*. 2003;62(11):1087-1095. doi:10.1093/jnen/62.11.1087
- 562 35. Chad JA, Pasternak O, Salat DH, Chen JJ. Re-examining age-related differences in white
563 matter microstructure with free-water corrected diffusion tensor imaging. *Neurobiol Aging*.
564 2018;71:161-170. doi:10.1016/j.neurobiolaging.2018.07.018
- 565 36. Hupfeld KE, Geraghty JM, McGregor HR, Hass CJ, Pasternak O, Seidler RD. Differential
566 Relationships Between Brain Structure and Dual Task Walking in Young and Older Adults.
567 *Front Aging Neurosci*. 2022;14:809281. doi:10.3389/fnagi.2022.809281
- 568 37. House MJ, St. Pierre TG, Kowdley KV, et al. Correlation of proton transverse relaxation
569 rates (R_2) with iron concentrations in postmortem brain tissue from alzheimer's disease
570 patients. *Magn Reson Med*. 2007;57(1):172-180. doi:10.1002/mrm.21118
- 571 38. Mitsumori F, Watanabe H, Takaya N. Estimation of brain iron concentration in vivo using a
572 linear relationship between regional iron and apparent transverse relaxation rate of the
573 tissue water at 4.7T. *Magn Reson Med*. 2009;62(5):1326-1330. doi:10.1002/mrm.22097
- 574 39. Schenker C, Meier D, Wichmann W, Boesiger P, Valavanis A. Age distribution and iron
575 dependency of the T2 relaxation time in the globus pallidus and putamen. *Neuroradiology*.
576 1993;35(2):119-124. doi:10.1007/BF00593967
- 577 40. Tsai S, Posse S, Lin Y, et al. Fast mapping of the T_2 relaxation time of cerebral metabolites
578 using proton echo-planar spectroscopic imaging (PEPSI). *Magn Reson Med*.
579 2007;57(5):859-865. doi:10.1002/mrm.21225
- 580 41. Träber F, Block W, Lamerichs R, Gieseke J, Schild HH. ^1H metabolite relaxation times at
581 3.0 tesla: Measurements of T1 and T2 values in normal brain and determination of regional

- 582 differences in transverse relaxation. *J Magn Reson Imaging*. 2004;19(5):537-545.
583 doi:10.1002/jmri.20053
- 584 42. Wyss PO, Bianchini C, Scheidegger M, et al. In vivo estimation of transverse relaxation time
585 constant (T_2) of 17 human brain metabolites at 3T: T_2 of 17 Human Brain Metabolites at
586 3T. *Magn Reson Med*. 2018;80(2):452-461. doi:10.1002/mrm.27067
- 587 43. Hetherington HP, Mason GF, Pan JW, et al. Evaluation of cerebral gray and white matter
588 metabolite differences by spectroscopic imaging at 4.1T. *Magn Reson Med*. 1994;32(5):565-
589 571. doi:10.1002/mrm.1910320504
- 590 44. An L, Li S, Shen J. Simultaneous determination of metabolite concentrations, T_1 and T_2
591 relaxation times. *Magn Reson Med*. 2017;78(6):2072-2081. doi:10.1002/mrm.26612
- 592 45. Mlynárik V, Gruber S, Moser E. Proton T_1 and T_2 relaxation times of human brain
593 metabolites at 3 Tesla: METABOLITE T_1 AND T_2 IN HUMAN BRAIN AT 3 T. *NMR Biomed*.
594 2001;14(5):325-331. doi:10.1002/nbm.713
- 595 46. Deoni SCL, Peters TM, Rutt BK. High-resolution T_1 and T_2 mapping of the brain in a
596 clinically acceptable time with DESPOT1 and DESPOT2. *Magn Reson Med*.
597 2005;53(1):237-241. doi:10.1002/mrm.20314
- 598 47. Schmitt P, Griswold MA, Jakob PM, et al. Inversion recovery TrueFISP: Quantification of T_1
599 , T_2 , and spin density. *Magn Reson Med*. 2004;51(4):661-667. doi:10.1002/mrm.20058
- 600 48. Fujita S, Hagiwara A, Hori M, et al. Three-dimensional high-resolution simultaneous
601 quantitative mapping of the whole brain with 3D-QALAS: An accuracy and repeatability
602 study. *Magn Reson Imaging*. 2019;63:235-243. doi:10.1016/j.mri.2019.08.031
- 603 49. Knight MJ, McCann B, Tsivos D, Couthard E, Kauppinen RA. Quantitative T1 and T2 MRI
604 signal characteristics in the human brain: different patterns of MR contrasts in normal
605 ageing. *Magn Reson Mater Phys Biol Med*. 2016;29(6):833-842. doi:10.1007/s10334-016-
606 0573-0
- 607 50. Gudmundson AT, Koo A, Virovka A, et al. Meta-analysis and open-source database for in
608 vivo brain Magnetic Resonance spectroscopy in health and disease. *Anal Biochem*.
609 2023;676:115227. doi:10.1016/j.ab.2023.115227
- 610 51. Tal A. The future is 2D : SPECTRAL-TEMPORAL fitting of dynamic MRS data provides
611 exponential gains in precision over conventional approaches. *Magn Reson Med*.
612 2023;89(2):499-507. doi:10.1002/mrm.29456
- 613 52. Zöllner HJ, Davies-Jenkins C, Simicic D, Tal A, Sulam J, Oeltzschner G. Simultaneous
614 multi-transient linear-combination modeling of MRS data improves uncertainty estimation.
615 Published online November 4, 2023. doi:10.1101/2023.11.01.565164
- 616 53. Clarke WT, Ligneul C, Cottaar M, Ip IB, Jbabdi S. Universal dynamic fitting of magnetic
617 resonance spectroscopy. *Magn Reson Med*. 2024;91(6):2229-2246.
618 doi:10.1002/mrm.30001

- 619 54. Kirov II, Tal A. Potential clinical impact of multiparametric quantitative MR spectroscopy in
620 neurological disorders: A review and analysis. *Magn Reson Med.* 2020;83(1):22-44.
621 doi:10.1002/mrm.27912
- 622 55. Eylers VV, Maudsley AA, Bronzlik P, Dellani PR, Lanfermann H, Ding XQ. Detection of
623 Normal Aging Effects on Human Brain Metabolite Concentrations and Microstructure with
624 Whole-Brain MR Spectroscopic Imaging and Quantitative MR Imaging. *Am J Neuroradiol.*
625 2016;37(3):447-454. doi:10.3174/ajnr.A4557
- 626